等待開盤 09-20 09:30:00 美东时间
+0.130
+2.37%
Ladenburg Thalmann analyst Aydin Huseynov maintains Corvus Pharma (NASDAQ:CRVS) with a Buy and raises the price target from $12 to $21.
09-17 00:37
U.S. stocks were mixed, with the Dow Jones index gaining around 200 points on M...
09-16 22:03
Shares of Corvus Pharmaceuticals (NASDAQ:CRVS) gained on Tuesday after the company announced the beginning of a Phase 3 registrational trial for its lead candidate, soquelitinib, in peripheral T-cell ...
09-11 02:43
Shares of Fortinet, Inc. (NASDAQ:FTNT) rose sharply in today's pre-market tradi...
08-07 18:04
Corvus Pharmaceuticals - Sales Agreement Prospectus Covering Offering of up to ...
08-07 05:35
Corvus Pharmaceuticals Inc Files for Mixed Shelf of up to $200 Mln – SEC Filing
08-07 05:33
Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.07) per share whic...
08-07 04:02
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024...
08-07 04:01
Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for ...
08-01 20:30
Corvus Pharmaceuticals Inc: On Track to Initiate Patient Enrollment in Our Regi...
08-01 20:30